GENERAL COMMENTS
-Please include a paragraph regarding the impact of gaps in these parameters on coronary imaging tests and coronary artery disease on invasive coronary angiography -Also, if possible, any data regarding the association of these gaps with future major CV events REVIEWER A.R. van Rosendae Leiden, The Netherlands REVIEW RETURNED 09-May-2017
This interesting an study addressed an important topic; to reduce the amount of symptomatic patients presenting to their cardiologist who refers for non-invasive coronary testing by improving primary preventive care of CAD. Results showed among patients from the promise trial that certain groups could be identified who were less well treated for their risk factors. Identification of these risk groups can target governmental actions on increase on primary prevention especially among those patients.
Could the authors describe the definitions of hyperlipidemia and hypertension in the methods sections? Because some studies include all statin users as patients with hyperlipidemia and the same for hypertension and anti-hypertensives. Although the indication of an anti-hypertensive could be different than hypertension.
In the results the authors only mention odds ratio's (appartently according to the table these are adjusted odds ratio's). Why did the authors not also mention frequencies/percentages. This may give more feeling for the amount of difference between groups.
1. Please include a paragraph regarding the impact of gaps in these parameters on coronary imaging tests and coronary artery disease on invasive coronary angiography
We agree with the reviewer that this is an important point but we did not explore the association of gaps with subsequent imaging, CAD diagnosis, or invasive coronary angiography. We did not explore this association because all patients were required to undergo testing to enter the trial, the ability to detect and diagnose CAD was related to the type of test patients underwent (anatomic vs. functional imaging), and invasive coronary angiography referral was highly correlated with test type and test results, rather than reflecting nuances in medications.
However, we have examined patient factors associated with other outcomes. In the Discussion section, paragraph 4, we now write: "We did not examine the association of gaps in care with subsequent imaging, CAD diagnosis, or invasive coronary angiography. In prior work, we showed that new initiation of an aspirin, statin, beta-blocker, or ACEi/ARB was not associated with the rate of adverse cardiovascular events over a median follow-up period of 25 months in adjusted models. We have also reported that absence of hypertension, dyslipidemia, and tobacco use are associated with a lower rate of adverse cardiovascular events. We also found that treatment gaps among patients with hypertension or diabetes were not associated with an increased risk of adverse cardiovascular events. In contrast, treatment gaps among patients with dyslipidemia were associated with an increased risk of adverse cardiovascular events." 2. Also, if possible, any data regarding the association of these gaps with future major CV events Please see our response to the reviewer's comment #1. We now examine the association of gaps in care with future major cardiovascular events among patients with hypertension, diabetes, or dyslipidemia. In the Results section, Variation in Preventive Care Gaps Between Higher and Lower Risk Symptomatic Patients subsection, we write: "For the combined endpoint of death, myocardial infarction, or hospitalization for unstable angina, there was no association between having a treatment gap and the risk of an adverse event among patients with hypertension or diabetes. However, for patients with dyslipidemia, the absence of a treatment gap was associated with a lower risk of an adverse event (HR 0.74, 95% CI 0.55-0.98)."
In addition, please see the sentence we added to the Discussion section, paragraph 4 (in our response to the reviewer's comment #1), about the association between gaps and future CV events.
Reviewer #2's Comments:
1. This interesting an study addressed an important topic; to reduce the amount of symptomatic patients presenting to their cardiologist who refers for non-invasive coronary testing by improving primary preventive care of CAD. Results showed among patients from the promise trial that certain groups could be identified who were less well treated for their risk factors. Identification of these risk groups can target governmental actions on increase on primary prevention especially among those patients.
We appreciate the reviewer's comments.
2. Could the authors describe the definitions of hyperlipidemia and hypertension in the methods sections? Because some studies include all statin users as patients with hyperlipidemia and the same for hypertension and anti-hypertensives. Although the indication of an anti-hypertensive could be different than hypertension.
Because PROMISE was a pragmatic trial, diagnoses were identified and defined by physicians at the participating clinics. We did not consider all statin users to be patients with dyslipidemia or all antihypertensive users to be patients with hypertension. To further clarify this, we have made the following addition to the Methods section, paragraph 3: "Because PROMISE was a pragmatic trial, diagnoses were identified and defined by physicians at the participating clinics rather than with studyspecific criteria."
3. In the results the authors only mention odds ratio's (appartently according to the table these are adjusted odds ratio's). Why did the authors not also mention frequencies/percentages. This may give more feeling for the amount of difference between groups.
We focused on odds ratios in order to highlight areas of disparity after adjusting for potential confounders. However, frequencies/percentages are fully reported in Table 2 . 
GENERAL COMMENTS
In the revised version of the manuscript, the association between treatment gaps and outcome (death/MI, UA) have been added, showing that patients with dyslipidemia and no treatment gap were at lower risk. This highlights the importance of the current study. I would suggest to include this messege into the abstract. Furtmerore, I would suggest not to state that the absence of a treatment gap was associated with lower risk but that the presence of a treatment gap was associated with increased risk for the combine endpoint.
VERSION 2 -AUTHOR RESPONSE
Reviewer #1's Comments:
1. I thank the authors for their recent editing and corrections. I have no further comments.
Thank you.
Reviewer #2's Comments:
1. I would suggest to include this messege into the abstract. Furtmerore, I would suggest not to state that the absence of a treatment gap was associated with lower risk but that the presence of a treatment gap was associated with increased risk for the combine endpoint.
We appreciate the reviewer's suggestions. In the Abstract, we have added the following statement: "For patients with dyslipidemia, the presence of a treatment gap was associated with a higher risk of an adverse event (HR 1.35, 95% CI 1.02-1.82)."
In the Results section of the manuscript, Variation in Preventive Care Gaps Between Higher and Lower Risk Symptomatic Patients subsection, we now write: "For patients with dyslipidemia, the presence of a treatment gap was associated with a higher risk of an adverse event (HR 1.35, 95% CI 1.02-1.82)."
